 AstraZeneca PLC LSE:AZN announced that the US Food and Drug Administration FDA has approved the companys Imjudo tremelimumab drug in combination with Imfinzi durvalumab for treatment of adult patients with unresectable hepatocellular carcinoma HCC, the most common type of liver cancer. The approval is based on results from the HIMALAYA Phase III trial, which showed that a single priming dose of the anti-CTLA-4 antibody Imjudo added to the anti-PD-L1 antibody Imfinzi reduced the risk of death by 22 compared with sorafenib, the pharmaceuticals company said in a statement. 